Charles Schwab Investment Management Inc. Increases Holdings in Novavax, Inc. (NASDAQ:NVAX)

Charles Schwab Investment Management Inc. lifted its position in Novavax, Inc. (NASDAQ:NVAX) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,365,414 shares of the biopharmaceutical company’s stock after purchasing an additional 39,906 shares during the period. Charles Schwab Investment Management Inc. owned 0.85% of Novavax worth $10,978,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Victory Capital Management Inc. increased its position in shares of Novavax by 12.0% during the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 2,072 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Novavax during the 3rd quarter worth about $527,000. Massachusetts Financial Services Co. MA boosted its stake in shares of Novavax by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 93,457 shares of the biopharmaceutical company’s stock worth $1,180,000 after acquiring an additional 18,229 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Novavax by 26.7% during the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after acquiring an additional 517,727 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Novavax by 33.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 79,783 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 20,127 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on NVAX shares. BTIG Research started coverage on shares of Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. Finally, TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.00.

Novavax Trading Down 1.6 %

Shares of NVAX stock opened at $7.60 on Friday. The company’s fifty day simple moving average is $8.25 and its 200-day simple moving average is $9.53. Novavax, Inc. has a 52 week low of $3.81 and a 52 week high of $23.86. The company has a market cap of $1.22 billion, a PE ratio of -3.36, a P/E/G ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same period in the prior year, the business earned ($1.44) earnings per share. Equities research analysts expect that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Insider Activity at Novavax

In related news, Director James F. Young sold 4,600 shares of the business’s stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total value of $39,008.00. Following the sale, the director now directly owns 57,160 shares in the company, valued at $484,716.80. The trade was a 7.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.00% of the stock is currently owned by insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.